KNSA
Kiniksa Pharmaceuticals International, Plc
A biopharmaceutical company that makes medicines for inflammatory diseases, including ARCALYST, the first and only FDA-approved therapy for recurrent pericarditis, a painful swelling of the sac around the heart. Kiniksa was founded in 2015 by a group of former colleagues from an earlier biotech firm who reunited to keep developing treatments for rare conditions. The name Kiniksa is an invented, distinctive-sounding corporate word with no traditional meaning.
CINS: G5269C1011 holder
Jun 28, 2024 — Reclassified as KINIKSA PHARMACEUTICALS INTL (1:1)
Total Value
$13.16M
Total Shares
667.0K
Net Share Change
-47.9K
Activity
1 selling
Investor
Value
Shares
Weight
Change
